Kevin Charles Gorman - Jan 31, 2023 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role: Chief Executive Officer, Director
Signature: /s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol: NBIX
Transactions as of: Jan 31, 2023
Transactions value $: -$297,997
Form type: 4
Date filed: 2/2/2023, 04:19 PM
Previous filing: Jun 27, 2022
Next filing: Feb 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NBIX	Common Stock	Sale	-$298K	-2.71K	-0.58%	$110.08	465K	Jan 31, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2	Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $111.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Content

Sale of 2,707 shares of common stock issued upon vesting of 5,141 restricted stock units on January 31, 2023 to cover payroll and withholding taxes, with the balance of the shares (2,434) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $109.07 to $111.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.